HomeOwner SearchCategory Search
Visit USCOMultiple Drug Resistance-associated Protein 4 Exports the Cyclooxygenase-2 Product Prostaglandin E2 as a Possible Mechanism to Enhance Metastasis of Basal-like Breast Cancer
Text Registration
Copyright Title
Multiple Drug Resistance-associated Protein 4 Exports the Cyclooxygenase-2 Product Prostaglandin E2 as a Possible Mechanism to Enhance Metastasis of Basal-like Breast Cancer
Status
Published
on 14 Jan 2016
Year of Creation
2015
Copyright Claimant
Tyler Justin Kochel
Registration Number
TX0008157420
on 14 Jan 2016Copyright Summary
The U.S. Copyright record (Registration Number: TX0008157420) dated 14 Jan 2016, pertains to an electronic file (eService) titled "Multiple Drug Resistance-associated Protein 4 Exports the Cyclooxygenase-2 Product Prostaglandin E2 as a Possible Mechanism to Enhance Metastasis of Basal-like Breast Cancer" created in 2015. The copyright holder is Tyler Justin Kochel, known for their creative contributions in text registration. For any inquiries concerning this copyrighted material, kindly reach out to Tyler Justin Kochel.
Application Details
Registration Number
TX0008157420
Registration Date
1/14/2016
Year of Creation
2015
Agency Marc Code
DLC-CO
Record Status
New
Physical Description
Electronic file (eService)
First Publication Nation
United States
Notes
Rights Note: Diana G Zajic, ProQuest-CSA, LLC, 789 E. Eisenhower Parkway, Ann Arbor, MI, 48108-3218, United States, (800) 521-0600 xext77020, disspub@proquest.com
Statements
Application Title Statement: Multiple Drug Resistance-associated Protein 4 Exports the Cyclooxygenase-2 Product Prostaglandin E2 as a Possible Mechanism to Enhance Metastasis of Basal-like Breast Cancer
Author Statement: Tyler Justin Kochel Citizenship: not known Authorship: text
© 2024 reserved by Trademarkia
Show terms & conditions
Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice. Although LegalForce RAPC Worldwide P.C., dba Trademarkia P.C., is a law firm (the “Firm”), your use of this website does not establish an attorney-client relationship with the Firm. Such a relationship can only be established after the Firm decides that it is willing and able to accept the engagement after a conflict check and after a written retainer agreement is agreed upon between you and the Firm. Your use of this website is also subject to our Terms of Use and Privacy Policy. ** The entry level subscription is a bundled price which requires a minimum of two billing cycles, or 6 months.